{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"404"},{"groupId":"OG001","value":"200"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"405"},{"groupId":"OG001","value":"202"}],"units":"Participants"}],"description":"An AE was defined as any untoward medical occurrence in a study participant administered study drug and which does not necessarily have to have a causal relationship with this study drug. The number of participants who experienced an AE is presented.","groups":[{"description":"Participants received pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m\\^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m\\^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m\\^2 IV Q3W until progression. (Participants who received pembrolizumab 200 mg IV Q3W for up to 2 years but experienced disease progression, were eligible to receive a second course of pembrolizumab monotherapy 200 mg IV Q3W, at the investigator's discretion, for up to 1 additional year.)","id":"OG000","title":"Pembrolizumab+Pemetrexed+Platinum Chemotherapy Followed by Pembrolizumab+Pemetrexed"},{"description":"Participants received saline placebo IV PLUS pemetrexed 500 mg/m\\^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m\\^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by saline placebo IV PLUS pemetrexed 500 mg/m\\^2 IV Q3W until progression. (Effective 23-Dec-2019, participants discontinued saline placebo. If documented disease progression had occurred, and participants receiving Control met certain criteria, they were eligible to switch over to receive pembrolizumab monotherapy Q3W for the remainder of the study.)","id":"OG001","title":"Control"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The analysis population consisted of all randomized participants who received ≥1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"Up to approximately 21 months (Serious AEs: Up to 90 days after last dose of study treatment; Other AEs: Up to 30 days after last dose of study treatment)","title":"Number of Participants Who Experienced an Adverse Event (AE)","type":"SECONDARY","unitOfMeasure":"Participants"}